Other research, however, identified, out of a total of 176 cases diagnosed as Bells palsy, HSV-1 in 31 cases (18%) and herpes zoster in 45 cases (26%).In addition, HSV-1 infection is associated with demyelination of nerves. This nerve damage mechanism is different from the above-mentioned—that edema, swelling and compression of the nerve in the narrow bone canal is responsible for nerve damage. Demyelination may not even be directly caused by the virus, but by an unknown immune response. Diagnosis
Bells palsy is a diagnosis of exclusion, meaning it is diagnosed by elimination of other reasonable possibilities. By definition, no specific cause can be determined. There are no routine lab or imaging tests required to make the diagnosis. The degree of nerve damage can be assessed using the House-Brackmann score. One study found that 45% of patients are not referred to a specialist, which suggests that Bells palsy is considered by physicians to be a straightforward diagnosis that is easy to manage.Other conditions that can cause similar symptoms include herpes zoster, Lyme disease, sarcoidosis, stroke, and brain tumors. Differential diagnosis
Once the facial paralysis sets in, many people may mistake it as a symptom of a stroke; however, there are a few subtle differences. A stroke will usually cause a few additional symptoms, such as numbness or weakness in the arms and legs. And unlike Bells palsy, a stroke will usually let patients control the upper part of their faces.
Allos Therapeutics, Inc. was acquired by Spectrum Pharmaceuticals, Inc. on September 5, 2012. Allos is a wholly owned subsidiary of Spectrum. Society and culture
Legal status
Pralatrexate was approved for medical use in  the United States in September 2009. Economics
Some oncologists, patient groups, and insurance companies criticized the cost of $30,000 a month or more, which could reach a total of $126,000 during a course of treatment. References
External links
"Pralatrexate". Drug Information Portal. U.S. National Library of Medicine. "Pralatrexate". NCI Drug Dictionary. National Cancer Institute. "Pralatrexate". National Cancer Institute.